The research program led by AdMeTech represents a unique, integrated multi-institutional, multi-disciplinary effort which expedites advancement, clinical evaluation and implementation of advanced imaging tools to improve screening, early diagnosis and treatment of prostate cancer.
Our Research Program is focused on the development, standardization clinical evaluation and large-scale implementation of imaging tools. Similarly to their impact on breast cancer management, advanced imaging tools will end the era of blind patient care and create the future of precisely-targeted, minimally-invasive biopsies and treatment, which can be performed in outpatient clinics, with minimal complications, discomfort and costs.
On December 1st, 2014, AdMeTech Foundation, jointly with the American College of Radiology and European Society of Urogenital Radiology, issued global standards for high quality service and reporting in prostate MRI, or PI-RADS Version 2 (v2).
In September 2016, AdMeTech completed phase II clinical trial of prostate MRI and PI-RADS v2 and presented its groundbreaking results at the First Global Summit on Precision Diagnosis for Prostate Cancer
Faina Shtern, MD
President, AdMeTech Foundation
Under Dr. Shtern’s stewardship, AdMeTech Foundation has led pioneering research and stimulated fundamental breakthroughs in prostate cancer imaging and minimally-invasive treatment, including:
- High precision 3 Tesla (3T) multi-parametric MRI (since 1998);
- Dedicated robotics for diagnosis and treatment (since 1998);
- Optical visualization and spectroscopy (since 2001); and
- Molecular imaging of prostate cancer (since 2001).
Since 1998, AdMeTech’s research has been extensively supported by federal, state and private grants, received numerous awards, and produced multiple publications in some of the most prestigious academic journals (see Landmark Accomplishments and Sources of Funding below).
Brain Trust as a Catalyst of Groundbreaking Innovation and its Transfer to Patients. AdMeTech’s Scientific Advisory Board, or “Brain Trust”, integrates the expertise and resources of the leading medical institutions into a comprehensive international research program, which facilitates the advancement of prostate cancer screening, diagnosis and treatment. By stimulating multi-disciplinary cross-fertilization and novel ideas, the Brain Trust makes it possible to support the early stages of high-impact research projects, when investment is at its lowest and impact is at its highest, and before other funding entities are prepared to take a risk. The research accomplishments detailed below highlight the critical importance of AdMeTech’s Brain Trust to a cost-effective approach to research support.
Our research program addresses the fundamental challenges in prostate cancer care by facilitating creation, testing and implementation of advanced prostate imaging technologies for individualized patient care, including:
- Improved early detection of aggressive prostate cancer, which is critical for saving lives;
- Elimination of unnecessary procedures for benign and indolent disease;
- Improved guidance and monitoring of clinical care, including early assessment of cancer response to treatment; and
- Transition from radical surgery to precisely guided, minimally invasive focal treatment (“male lumpectomy”), which ensures effective cancer control and can be performed in outpatient clinics with drastically reduced complications, discomfort and costs.
- AdMeTech pioneered research support for every stage of high-precision, prostate dedicated 3 Tesla (3T) multi-parametric (mp) MRI, from concept development and early stages of testing at the University of Pennsylvania in 1998 to clinical validation at Harvard Medical School, University of California at San Francisco and Los Angeles, Memorial Sloan Kettering Cancer Center and many other leading academic institutions (see Research Phase I – IV).
- By 2005, based on the emergence of prostate mpMRI as one of the most promising diagnostic tools for prostate cancer, we established the International Prostate MRI Working Group, which integrated expertise and resources of the top scientific laboratories in order to expedite the advancement of research, testing and clinical implementation, including:
- Creation of standards in image creation, analysis and interpretation (PI-RADS) endorsed by the American College of Radiology and the European Society of Urogenital Radiology since 2011; and
- Designing a definitive multi-center clinical trial, assembling its research team and creating a formal partnership with the American College of Radiology Imaging Network (ACRIN), the NIH-funded clinical trial infrastructure.
- Leading retrospective, statistically powered phase II clinical trial and assembling a research team, including Harvard Medical School’s Brigham and Women’s, Massachusetts General and Boston Children’s Hospitals, as well as ACRIN’s Statistical Center at Brown University.
- AdMeTech established the field of molecular imaging of prostate cancer since 2001 and supported pioneering studies in PET and optical imaging at Johns Hopkins, Harvard Medical School, Boston University and other leading academic institutions (see Phase II –III).
- AdMeTech has pioneered support and development of robotics for prostate cancer biopsy and treatment at Johns Hopkins University since 1998 (see Phase I).
Major Sources of Funding
- Walter Robb Family Foundation
- Henry M. Jackson Foundation / Department of Defense
- Department of Defense Award # DAMD 17-03-2-0055 (2003 -2011)
- Department of Defense Award # W81XMH-09-1-0552 (2009 – 2013)
- Department of Defense Award # W81XWH-11-1-0077 (2010 – 2015)
- Massachusetts Department of Public Health (2013 – 2016)
We thank the executive leadership of the global pharmaceutical and imaging industry and the Prostate Cancer Foundation for their participation in and support of the semi-annual meetings of our Brain Trust in Molecular Imaging and International Prostate MRI Working Group: